Soligenix Total Assets 2010-2021 | SNGX

Soligenix total assets from 2010 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Soligenix Annual Total Assets
(Millions of US $)
2021 $27
2020 $20
2019 $8
2018 $10
2017 $10
2016 $10
2015 $7
2014 $7
2013 $8
2012 $5
2011 $8
2010 $9
2009 $9
Soligenix Quarterly Total Assets
(Millions of US $)
2021-12-31 $27
2021-09-30 $30
2021-06-30 $30
2021-03-31 $32
2020-12-31 $20
2020-09-30 $13
2020-06-30 $12
2020-03-31 $10
2019-12-31 $8
2019-09-30 $8
2019-06-30 $9
2019-03-31 $10
2018-12-31 $10
2018-09-30 $13
2018-06-30 $6
2018-03-31 $7
2017-12-31 $10
2017-09-30 $6
2017-06-30 $7
2017-03-31 $8
2016-12-31 $10
2016-09-30 $8
2016-06-30 $5
2016-03-31 $6
2015-12-31 $7
2015-09-30 $6
2015-06-30 $5
2015-03-31 $6
2014-12-31 $7
2014-09-30 $6
2014-06-30 $6
2014-03-31 $7
2013-12-31 $8
2013-09-30 $8
2013-06-30 $9
2013-03-31 $4
2012-12-31 $5
2012-09-30 $5
2012-06-30 $6
2012-03-31 $7
2011-12-31 $8
2011-09-30 $9
2011-06-30 $6
2011-03-31 $7
2010-12-31 $9
2010-09-30 $11
2010-06-30 $12
2010-03-31 $7
2009-12-31 $9
2009-09-30 $10
2009-06-30 $7
2009-03-31 $8
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.017B $0.001B
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Biohaven Pharmaceutical Holding (BHVN) United States $9.944B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Emergent Biosolutions (EBS) United States $1.444B 6.18
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.509B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Ambrx Biopharma (AMAM) United States $0.159B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00